MX2022013029A - Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. - Google Patents

Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.

Info

Publication number
MX2022013029A
MX2022013029A MX2022013029A MX2022013029A MX2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A MX 2022013029 A MX2022013029 A MX 2022013029A
Authority
MX
Mexico
Prior art keywords
methods
compositions
neuropsychiatric disorders
treating neuropsychiatric
treating
Prior art date
Application number
MX2022013029A
Other languages
English (en)
Inventor
Alon Seifan
Original Assignee
Honeybrains Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honeybrains Llc filed Critical Honeybrains Llc
Publication of MX2022013029A publication Critical patent/MX2022013029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Como se describe a continuación, la presente invención presenta composiciones y métodos para tratar trastornos de la salud mental y/o del comportamiento y sus síntomas asociados.
MX2022013029A 2020-04-17 2021-04-16 Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. MX2022013029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011932P 2020-04-17 2020-04-17
US202063111156P 2020-11-09 2020-11-09
PCT/US2021/027641 WO2021211944A1 (en) 2020-04-17 2021-04-16 Compositions and methods for treating neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
MX2022013029A true MX2022013029A (es) 2023-01-16

Family

ID=78084126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013029A MX2022013029A (es) 2020-04-17 2021-04-16 Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.

Country Status (11)

Country Link
US (4) US20230218583A1 (es)
EP (1) EP4136103A4 (es)
JP (1) JP7505024B2 (es)
KR (1) KR20230005229A (es)
CN (1) CN116134048A (es)
AU (1) AU2021255701A1 (es)
BR (1) BR112022021011A2 (es)
CA (1) CA3180330A1 (es)
IL (1) IL297333A (es)
MX (1) MX2022013029A (es)
WO (1) WO2021211944A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136103A4 (en) * 2020-04-17 2024-05-15 HB Biotech, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
CZ304359B6 (cs) * 1998-07-10 2014-03-26 Novartis Ag Farmaceutická kombinační kompozice
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
TW200306799A (en) * 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
US20060089335A1 (en) * 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
US20110269717A1 (en) 2006-07-17 2011-11-03 Braincells Inc. Neurogenesis by modulating angiotensin
US20080249178A1 (en) * 2007-03-22 2008-10-09 Guosong Liu Magnesium compositions and uses thereof for increasing lifespan
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
CN101890165A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 降压组合物及用途
CN102266559A (zh) * 2010-06-01 2011-12-07 王丽燕 包含替米沙坦盐和钙离子拮抗剂的药物组合物
KR101378973B1 (ko) 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
PT2938328T (pt) 2012-12-27 2023-09-26 Hennig Arzneimittel Gmbh&Co Kg Fármaco monolítico para a libertação modificada de uma combinação de princípios ativos
CN106574268B (zh) 2014-05-22 2021-02-05 阿尔尼拉姆医药品有限公司 血管紧张素原（AGT）iRNA组合物及其使用方法
EP2979691A1 (en) * 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
TWI721987B (zh) 2015-06-01 2021-03-21 開曼群島商盧郡控股（開曼）有限公司 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物
US10626105B2 (en) 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
CN109010261B (zh) 2017-06-22 2020-11-06 四川大学 一种小分子药物原位相变凝胶缓释***及其制备方法
EP4136103A4 (en) * 2020-04-17 2024-05-15 HB Biotech, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES

Also Published As

Publication number Publication date
BR112022021011A2 (pt) 2022-12-27
EP4136103A4 (en) 2024-05-15
JP2023522206A (ja) 2023-05-29
EP4136103A1 (en) 2023-02-22
CN116134048A (zh) 2023-05-16
US20230218583A1 (en) 2023-07-13
US11583520B2 (en) 2023-02-21
US11491142B2 (en) 2022-11-08
KR20230005229A (ko) 2023-01-09
WO2021211944A1 (en) 2021-10-21
JP7505024B2 (ja) 2024-06-24
IL297333A (en) 2022-12-01
US20220023264A1 (en) 2022-01-27
US20230310383A1 (en) 2023-10-05
CA3180330A1 (en) 2021-10-21
AU2021255701A1 (en) 2022-12-08
US20220008396A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
PH12019500196A1 (en) Compounds and compositions and uses thereof
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
MX2020002762A (es) Composiciones y métodos para tratar una lesión cerebral.
WO2015143447A3 (en) Methods for treating neurological disorders
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
MA48939B1 (fr) Compositions comprenant des souches bactériennes
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2022013029A (es) Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CR20220228A (es) Anticuerpos trem2 y usos de estos
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease